- Home
- Laboratory Improvement
- CAP eCC
The College of American Pathologists (CAP) eCC (electronic Cancer Checklists) enables pathologists to use the CAP Cancer Protocols directly within their laboratory information system (LIS) workflow and to ensure that each report is completed with the necessary required elements. Most anatomic pathology (AP)-LIS vendors offer a CAP eCC synoptic module for reporting on surgical cancer resections and selected biopsies.
CAP eCC Releases
The CAP releases eCC templates on a rolling basis, coordinating as much as possible with the posting of new and revised Cancer Protocols and Cancer Biomarker Reporting Templates. A few weeks prior to each Major or Agile release, email notifications are sent out to all licensed CAP eCC users.
Benefits of the CAP eCC
- Integrates into pathologist AP-LIS workflow
- Supports and aids the pathologist in the diagnostic process
- Standardizes the collection and reporting of cancer patient data
- Facilitates communication between pathologists, clinicians and cancer registrars
- Helps to advance the pathologist role as chief diagnostician and a leader in the patient care process
- Improves and supports information exchange and data interoperability
- Provides automated access to patient data through work with vendors
eCC XML Comparator Tool
The eCC XML COMPARATOR tool compares two versions of the eCC XML files from CAP repository or local repository. This web-based tool allows for comparison of two versions of the eCC checklist to view "File Comparison Report".
Structure Data Capture (SDC)
SDC is a new technology for representing technology-agnostic forms using SDC schema definition XML format. Starting in 2019, all eCC templates will be in SDC format.
Learn more about SDC by reading the SDC System manual that explains SDC web tool navigation, features, and functionality.
Licensing of the CAP eCC
The following lists some of the vendors who integrate the CAP eCC into their AP-LIS software products:
- Cerner CoPathPlus
- Dolbey
- Epic Beaker
- mTuitive (CAP's partner for CAP eFRM™)
Interfaces and/or integrations with:- Cerner Millennium
- Cortex
- Meditech
- Sunquest Copath
- Other LIS systems
- Novopath
- Psyche Systems
- Sunquest Powerpath
- Voicebrook
Contact the CAP for more information about licensing and using the CAP eCC for cancer reporting at your institution.
CAP eFRM
The eCC is now available to users in a standardized software implementation using CAP eFRM.
eCC Related Resources
Access resources from the CAP and other organizations to learn more about eCC.
Collaboration With Other Organizations
The CAP eCC is based on the CAP Cancer Protocols and is produced under the guidance of the CAP Pathology Electronic Reporting (PERT) Committee, along with close interaction and advisement of the Cancer Committee.
The eCC is developed in collaboration with and partially underwritten by the Centers for Disease Control and Prevention (CDC). Additional collaborators include the American Joint Committee on Cancer (AJCC), Cancer Care Ontario (CCO), and the North American Association of Central Cancer Registries (NAACCR).
The CAP currently is working with the California Cancer Registry (CCR) to offer the benefits of the eCC to California laboratories. CCR and the CAP are seeking out laboratories interested in participating in an ongoing project using the eCC to directly transfer cancer data to the central registry.
Testimonials
The CAP eCC is easy to use, improves efficiency and removes doubt about report findings. There is clarity of information which is presented in a crisp, consistent format. It gives confidence to health care providers who are involved in treatment care plans, since it is easier and quicker to see the data needed for treatment discussions and decisions.
Dr. Dimitrios Divaris, chief of pathology at Grand River Hospital and clinical advisor at Cancer Care Ontario
My surgeon provided me a copy of my pathology report. Because of its clarity and completeness, I was then able to research the facts and validate my oncologist's proposed treatment plans. I could truly give informed consent when asked my preference in terms of chemotherapy regimens, radiation therapy, targeted molecular therapy and hormone therapy. Knowing my treatment plan was in line with recommended practice gave me confidence in my health care providers and more importantly, hope for a positive outcome.
Marianne Luettschwager, patient and cancer survivor
Learn more about the other cancer reporting tools.
Contact Information